Drug intelligence / Profile preview

Weiru Xitong ointment

Development stage: Preclinical
Lead developer: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Administration: Topical

Overview

**Weiru Xitong ointment** is an investigational topical ointment evaluated for breast hyperplasia, including breast pain associated with this condition. A prospective, randomized, double-blind, placebo-controlled clinical study was registered in China in May 2020 by The Second Affiliated Hospital of Guangzhou University of Chinese Medicine. Public registry information identifies the dosage form and therapeutic setting but does not disclose the ointment's active ingredients, molecular targets, or pharmacologic mechanism. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=48014))

Other names: 维乳息痛软膏

Beyond the preview

Go deeper on Weiru Xitong ointment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weiru Xitong ointment.

Explore the full profile